Bausch Health Companies Inc has seen a remarkable surge in its stock price, reflecting strong financial results and positive market sentiment.
Shares of Bausch Health Companies Inc (BHC.TO) are rising today, up 27.13% to CA$8.34. This significant increase follows the company's impressive Q2 earnings report, which showcased robust revenue growth and exceeded analysts' expectations.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$2.39B
52W high
$11.97
52W low
$6.10
1W change
+1.86%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to rise 6.8% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
+6.8% Upside
Current Price
C$6.56
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
46.5%
Annualized
90-Day Vol
41.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$5.49
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$6.18 | C$5.27 – C$7.26 |
| 60 trading days | C$5.82 | C$4.64 – C$7.31 |
| 90 trading days | C$5.49 | C$4.16 – C$7.24 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should note the strong quarterly performance and raised guidance, which could signal a turnaround for Bausch Health after a challenging period.
Bausch Health Reports $2.85 Billion in Revenue
The company achieved a 12.7% increase in revenue year-over-year, surpassing analyst expectations and raising full-year guidance.
Bull case
Bausch Health reported revenues of $2.85 billion for Q2 2026, a 12.7% increase from the previous year, beating estimates by 7.62%. Adjusted earnings per share rose to $1.26, reflecting a 40% increase from last year. This performance highlights the strength of Bausch's product portfolio and effective market execution.
Bear case
Despite today's surge, Bausch Health has faced challenges, including a recent negative return of -8.3% over the past month. The Zacks Rank of #5 indicates potential underperformance in the near term, suggesting that investors should remain cautious.
Advertisement
Strong Q2 Earnings Drive Stock Surge
Bausch Health's recent earnings report revealed a total revenue of $2.85 billion for the second quarter of 2026, a 13% increase from the previous year. The company's adjusted EBITDA also rose significantly, showcasing its operational strength. These results have instilled confidence among investors, leading to today's stock price increase.
Market Response and Future Outlook
The market's positive reaction to Bausch's earnings highlights a potential shift in sentiment towards the company. With raised guidance for the full year and a focus on long-term value creation, investors are optimistic about Bausch's ability to sustain this momentum. However, caution is warranted given the recent underperformance relative to the broader market.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
